A New Heart Valve for Aortic Conditions
SBIR Phase II: Novel Hyaluronan Enhanced Polymeric Trans-Catheter Aortic Valve
['FUNDING_SBIR_2'] · YOUNGHEARTVALVE LLC · NIH-11193821
This project is developing a new type of artificial heart valve for people who need their aortic valve replaced, aiming for a longer-lasting option that doesn't require daily blood thinners.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YOUNGHEARTVALVE LLC (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11193821 on ClinicalTrials.gov |
What this research studies
We are working on a new heart valve called the Rejuvenate™ Heart Valve, designed to be placed using a catheter, which is a less invasive procedure. This valve uses special flexible materials that are treated with hyaluronan, a natural substance, to help prevent it from hardening over time and reduce the need for blood-thinning medications. It also features a unique sealing technology that helps the valve fit perfectly once implanted, similar to how a surgically sewn-in valve would. Our goal is to make this life-saving technology more accessible and affordable worldwide.
Who could benefit from this research
Good fit: This research is for patients who need an aortic heart valve replacement and could benefit from a less invasive procedure and a valve designed for long-term use without chronic anticoagulation.
Not a fit: Patients who do not have aortic valve disease or who are not candidates for a transcatheter valve replacement would not directly benefit from this specific development.
Why it matters
Potential benefit: If successful, this new heart valve could offer patients a durable replacement that avoids the need for lifelong blood thinners and the associated risks, while also being more affordable.
How similar studies have performed: While transcatheter aortic valve replacement (TAVR) is an established procedure, this project introduces novel materials and sealing technology aimed at improving longevity and reducing the need for blood thinners, which are significant advancements over current options.
Where this research is happening
ATLANTA, UNITED STATES
- YOUNGHEARTVALVE LLC — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TOMBA, TODD CHARLES — YOUNGHEARTVALVE LLC
- Study coordinator: TOMBA, TODD CHARLES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.